DER SPIEGEL (unsigned), 1990-08-12: Der Spiegel's 1990 report on Abel's book, published around the Hamburg cancer congress. It records the book's title, publisher, length and price (Hippokrates Verlag, Stuttgart; 112 pages; 28 DM), Abel's one-word verdict ('Niederschmetternd' – devastating), and the exceptions he himself drew: lymphomas, Hodgkin's disease, leukaemias, sarcomas and testicular cancer, plus neoadjuvant and adjuvant chemotherapy.
Abels Verdikt gegen die medikamentöse Therapie gilt ausdrücklich nicht für Lymphkrebsarten, Morbus Hodgkin, Leukämien, Sarkome und Keimzelltumoren bei Männern (Hodenkrebs).
Article body, para. 12 (web reproduction of the print issue)
DER SPIEGEL (unsigned), 1990-08-12: Der Spiegel's 1990 report on Abel's book, published around the Hamburg cancer congress. It records the book's title, publisher, length and price (Hippokrates Verlag, Stuttgart; 112 pages; 28 DM), Abel's one-word verdict ('Niederschmetternd' – devastating), and the exceptions he himself drew: lymphomas, Hodgkin's disease, leukaemias, sarcomas and testicular cancer, plus neoadjuvant and adjuvant chemotherapy. Confirms the monograph exists and gives its German title: 'Die zystostatische Chemotherapie fortgeschrittener epithelialer Tumoren. Eine kritische Bestandsaufnahme'. English translation of the excerpt: 'Abel's verdict against drug therapy expressly does not apply to lymphomas, Hodgkin's disease, leukaemias, sarcomas and germ-cell tumours in men (testicular cancer).' Note: the same page says the verdict covers 'fortgeschrittene epitheliale Malignome', which cause 'at least 80 percent' of cancer deaths. No byline; German-language primary news record. Study type: news.
